Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.86 |
| ▸ | NPC1 | O15118 | 3/20 | 0.86 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066827 | 0.87 | HCAR2 (0.83) | RAB9ANPC1HCAR2SMN1; SMN2POLB | |
| SCHEMBL5301445 | 0.86 | RAB9A (0.70) | RAB9ANPC1HCAR2KDM4ESMN1; SMN2 | |
| SCHEMBL5307210 | 0.85 | NPC1 (0.69) | RAB9ANPC1HCAR2KDM4ESMN1; SMN2 | |
| SCHEMBL5296521 | 0.85 | NPC1 (0.77) | RAB9ANPC1HCAR2KDM4ESMN1; SMN2 | |
| SCHEMBL5303546 | 0.82 | MAPK8 (0.66) | RAB9ANPC1HCAR2KDM4ESMN1; SMN2 | |
| SCHEMBL5065123 | 0.81 | NPC1 (0.64) | RAB9ANPC1KDM4ESMN1; SMN2POLB | |
| SCHEMBL5308463 | 0.80 | HCAR2 (0.64) | RAB9ANPC1HCAR2SMN1; SMN2POLB | |
| SCHEMBL5061223 | 0.80 | KDM4E (0.62) | RAB9ANPC1HCAR2KDM4ELTB4R | |
| SCHEMBL23413572 | 0.79 | NPC1 (0.76) | RAB9ANPC1KDM4ESMN1; SMN2POLB | |
| SCHEMBL5300923 | 0.78 | HCAR2 (0.65) | RAB9ANPC1HCAR2KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200468-A1 | 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-08-21 | — | — | US | disclosed |
| US-20080200468-A1 | 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-08-21 | — | — | US | disclosed |
| US-20080200468-A1 | 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-08-21 | — | — | US | disclosed |
| EP-1853579-A2 | 2-SUBSTITUTED 5-MEMBERED HETEROARYL CARBOXYLATES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006085113-A2 | 2-SUBSTITUTED 5-MEMBERED HETEROARYL CARBOXYLATES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200468-A1 | 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists | GPR84, GPR88, HCAR1 | RAB9A 565/4885NPC1 1995/4885HCAR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.